Weekly Research Analysts’ Ratings Changes for Stryker (SYK)

A number of research firms have changed their ratings and price targets for Stryker (NYSE: SYK):

  • 2/1/2018 – Stryker had its “market perform” rating reaffirmed by analysts at Citigroup Inc. They now have a $165.00 price target on the stock, up previously from $156.00. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 2/1/2018 – Stryker had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $165.00 price target on the stock.
  • 1/31/2018 – Stryker had its price target raised by analysts at Leerink Swann from $177.00 to $184.00. They now have an “outperform” rating on the stock.
  • 1/31/2018 – Stryker had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
  • 1/31/2018 – Stryker had its “buy” rating reaffirmed by analysts at Guggenheim.
  • 1/31/2018 – Stryker had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $170.00 price target on the stock.
  • 1/30/2018 – Stryker had its “hold” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $163.00 price target on the stock.
  • 1/26/2018 – Stryker had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $179.00 price target on the stock, up previously from $161.00.
  • 1/20/2018 – Stryker was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Despite trading above the broader industry in the last year, Stryker has been grappling with supply side issues in its spine business since long. Adding to our concerns, Stryker announced the voluntary product recall of the Oral Care lineup. The recall is likely to adversely impact the company’s sales and operating income. Moreover, volatility in foreign currency exchange is likely to impede Stryker’s growth in the coming quarters. On a brighter note, solid performance in the MAKO platform has been boosting Stryker’s revenues since long. An upbeat guidance for the full year instills investor confidence on the stock. Stryker’s acquisition-driven strategy is expected to expand existing product offerings across all business segments. Continued strong demand for hemorrhagic and ischemic stroke products and neuro-powered instruments are also likely to boost sales in the neurotechnology segment.”
  • 1/17/2018 – Stryker had its “hold” rating reaffirmed by analysts at Needham & Company LLC. They wrote, “On 1/9/18, SYK preannounced 4Q17 revenue that was above consensus. Management refrained from providing 2018 guidance, however, and plans to provide this on its 4Q17 call on Tuesday, 1/30/18. Although there was no guidance, management did indicate that tax reform would create a modest headwind” to its earnings in 2018. SYK placed 35 Mako systems in 4Q17, which was up modestly from 33 in 3Q17 and 32 in 4Q16; SYK noted that Mako helped to drive 10.5% US knee growth in 4Q17. Clearly 4Q17 was another strong quarter for SYK but we maintain our Hold rating given its valuation (2018E P/E of 22.5x, which is approximately in line with its large-cap peers’ median of 22.9x).””
  • 1/9/2018 – Stryker had its price target raised by analysts at Piper Jaffray Companies from $156.00 to $166.00. They now have an “overweight” rating on the stock.
  • 1/9/2018 – Stryker had its “buy” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $175.00 price target on the stock.
  • 1/5/2018 – Stryker had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $163.00 price target on the stock. They wrote, “Announced preliminary FY17 revenue of $3.5B, beating FactSet consensus of $3.4B.””
  • 1/2/2018 – Stryker was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating.
  • 1/2/2018 – Stryker had its “outperform” rating reaffirmed by analysts at Wells Fargo & Co. They now have a $174.00 price target on the stock, up previously from $166.00. They noted that the move was a valuation call. They noted that the move was a valuation call.

Shares of Stryker Corporation (NYSE:SYK) opened at $156.24 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.59 and a current ratio of 2.29. Stryker Corporation has a one year low of $123.84 and a one year high of $170.00. The firm has a market cap of $58,470.00, a P/E ratio of 58.30, a P/E/G ratio of 2.21 and a beta of 0.70.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.95 by $0.01. Stryker had a net margin of 8.20% and a return on equity of 24.56%. The firm had revenue of $3.47 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period in the prior year, the firm earned $1.78 earnings per share. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. analysts predict that Stryker Corporation will post 7.12 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, April 30th. Investors of record on Thursday, March 29th will be paid a dividend of $0.47 per share. The ex-dividend date is Wednesday, March 28th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.20%. Stryker’s payout ratio is 70.15%.

In other Stryker news, insider Graham A. Mclean sold 2,984 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $160.53, for a total value of $479,021.52. Following the transaction, the insider now directly owns 9,100 shares in the company, valued at $1,460,823. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Howard E. Cox, Jr. sold 7,400 shares of the stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $164.09, for a total transaction of $1,214,266.00. The disclosure for this sale can be found here. Insiders have sold 16,840 shares of company stock worth $2,749,989 over the last 90 days. Insiders own 7.40% of the company’s stock.

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply